FDA Targets Philips' Imaging Manufacturing Facility With Warning Letter
This article was originally published in The Gray Sheet
Executive SummaryFDA has cited Philips Medical Systems for more than 16 quality system deficiencies, including design controls, late reporting of device malfunctions and other violations concerning the firm’s computer tomography imaging and nuclear medicine products.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.